Identifikasi DRPs (Drug Related Problems) Pada Pasien Rawat Inap Diabetes Mellitus Tipe 2 Geriatri Di Rumah Sakit Umum Aisyiyah Ponorogo Tahun 2019

Diabetes mellitus is a metabolic disease characterized by hyperglycemia that occurs because the pancreas is unable to secrete insulin, insulin work disorders, or both, resulting in long-term damage and failure of various organs such as the eyes, kidneys, nerves, heart, and blood vessels when in a state of chronic hyperglycemia. An elderly patient (geriatric) is someone who reaches the age of 60 (sixty years) and over. Elderly patients generally experience decreased organ function and receive various kinds of drugs, making them prone to experiencing DRPs. DRPs are conditions associated with drug therapy that significantly or potentially interfere with desired clinical health outcomes. This study aims to identify the types of DRPs and to analyze the influence of age, sex, polypharmacy, comorbidities and length of stay on the incidence of DRPs in geriatric patients undergoing hospitalization. This research is a descriptive cross sectional study with 125 medical records for the period March - May 2019 at the Inpatient Installation of Aisyiyah Hospital, Ponorogo. The inclusion criteria in this study were geriatric patients aged over 60 years with a diagnosis of type 2 diabetes mellitus, receiving diabetes drug therapy during treatment at Aisyiyah Ponorogo Hospital and having complete medical record data. The results of the study of 125 patients studied, there were 78 patients (62.4%) who experienced DRPs. In the DRPs problem category there were 82 events with the following details: unnecessary drug therapy was 74 events (90.24%), adverse drug reaction was 3 events (3.66%), indications or symptoms were not handled as many as 3 events 3.66%), and the treatment effect was not optimal for 2 events (2.44%). Whereas in the category of causes of DRPs there were 91 causes with the following details: DRPs that occurred because of drug selection, there were 77 events (84.62%), 14 events (15.38%) in the choice of dose. There is a relationship between risk factors for polypharmacy and comorbidities with the incidence of DRPs. Polypharmacy p value = 0.015, comorbidities p value = 0.009 the value is